News Medical

European Medicines Agency approves first-ever treatment for hereditary factor X deficiency

Bio Products Laboratory, Limited (BPL) today announced that the European Medicines Agency has granted marketing authorisation for Coagadex. Coagadex is indicated for the treatment and prophylaxis of ...
WOOD-TV

Kedrion Biopharma Receives Orphan Drug Designation for COAGADEX® for Acquired Factor X Deficiency (aFXD) and Starts Clinical Trial to Evaluate Efficacy and Safety

FORT LEE, N.J., July 29, 2025 /PRNewswire/ -- Kedrion Biopharma is proud to announce that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Coagulation Factor X ...
WOOD-TV

Hereditary Factor X Deficiency (HFXD) Survey shows unmet need in patients with rare bleeding disorder

DURHAM, N.C., Aug. 16, 2022 /PRNewswire/ -- Bio Products Laboratory USA (BPL), a leading manufacturer of plasma-derived protein therapies, today presented initial data from the Hereditary Factor X ...
Business Insider

Kedrion Biopharma Marks Fourth Annual Hereditary Factor 10 Deficiency Day on October 10

Global biopharma company encourages education and awareness around a rare bleeding disorder. FORT LEE, N.J., Oct. 10, 2023 /PRNewswire/ -- Kedrion Biopharma, an international biopharmaceutical company ...
Business Insider

BPL Announces the Kick-off of the Hereditary Factor X Deficiency in America Survey

DURHAM, N.C., Sept. 28, 2021 /PRNewswire/ -- Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, with US offices in Durham, NC announced today the kick-off of ...
MarketWatch

Kedrion Biopharma Receives Orphan Drug Designation for COAGADEX(R) for Acquired Factor X Deficiency (aFXD) and Starts Clinical Trial to Evaluate Efficacy and Safety

The MarketWatch News Department was not involved in the creation of this content. FORT LEE, N.J., July 29, 2025 /PRNewswire/ -- Kedrion Biopharma is proud to announce that the U.S. Food and Drug ...